EICHORPublic-registry site landscape for NCT05387707, “Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis”, a Pruritus study sponsored by Cara Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05387707 (registry record) |
| Study title | Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis |
| Official title | A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis |
| Sponsor | Cara Therapeutics, Inc. |
| Condition(s) | Pruritus; Atopic Dermatitis |
| Phase | PHASE3 |
| Listed sites | 61 |
| Intervention(s) | difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05387707.
Eichor generates a preliminary site-risk snapshot for NCT05387707 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
